Milestone restarts PSVT NDA for etripamil; cash of $89.5M funds into 2026

Milestone Pharmaceuticals Inc.

2024-Q1 EPS reported -$0.21

NDA for etripamil in PSVT resubmitted after FDA Type A meeting; standard review expected, potential approval in H1 2025.
Cash, equivalents and short-term investments of $89.5M as of March 31, 2024, expected to fund operations into 2026.
No revenue in Q1 2024 vs $1.0M in Q1 2023; net loss of $10.4M improved from $15.0M a year ago.
R&D expense fell to $3.6M from $10.3M due to completion of Phase 3 PSVT studies.
March 2024 public offering of common shares and pre-funded warrants raised net proceeds of ~$32.2M for development and commercialization.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Milestone Pharmaceuticals Inc. reported first quarter ended March 31, 2024 results: revenue no revenue, net income net loss was $10.4 million.

Period: first quarter ended March 31, 2024
Revenue: no revenue
Net income: net loss was $10.4 million
Result: reported results

Exact text from the filing

Milestone Pharmaceuticals Inc. (the "Company") issued a press release announcing its financial results for the first quarter ended March 31, 2024

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Milestone Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-060221

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.